Clinical Trial: Vitamin D supplementation - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Vitamin D supplementation

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 172
Medication: Vitamin D
Location: CA|CT|MD|MO|OH|OR|PA|VA|WA
Contact Information

Funding:

National MS Society 

Description

Comparing the effectiveness of the current recommended amount of vitamin D supplementation versus high dose vitamin D supplementation at reducing MS disease activity, when added to standard therapy with glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries) in people with relapsing-remitting MS.

Share